NEEDHAM, Mass.--(BUSINESS WIRE)--Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that new preclinical data on its therapeutic antibody program, CDX-1127, was presented in a poster presentation at the 2011 American Society of Hematology (ASH) 53rd Annual Meeting in San Diego, CA. The presentation (poster #2861), entitled “Development of a Human Anti-CD27 Antibody with Efficacy in Lymphoma and Leukemia Models by Two Distinct Mechanisms,” describes proof of concept studies for CDX-1127 in preclinical models of lymphoma. CDX-1127 is a novel therapeutic antibody candidate that is currently being evaluated in a Phase 1 dose escalation clinical trial as a treatment for patients with hematologic malignancies and selected solid tumors.
